Emma Koehn

Dr Danielle McMullen The AMA has written to Prime Minister Anthony Albanese demanding action on AI generated ‘deepfakes', amid a string of

The Pharmaceutical Benefits Advisory Committee has recommended against a PBS listing of teplizumab for delaying the onset of type 1 diabetes, finding the proposal did not demonstrate the drug would be value for money.

Professor Steven Kahn The medication revolution in diabetes is showing no signs of slowing down, with at least three drug classes currently poised to reshape T2D treatment, the editor-in-chief of Diabetes Care says.

The Royal Australasian College of Physicians faced a $1.2 million bill for governance-related matters in 2025, in a year marked by board infighting and multiple extraordinary general meetings.

The Tasmanian Supreme Court has dismissed a negligence claim against a GP accused of delaying a patient's MS diagnosis by more than a year, finding

Metformin use is associated with prolonged gestation and fewer pre-term births but the evidence suggests it does not reduce rates of gestational diabetes, Australian researchers have found.

Tofacitinib may be a slower but safer alternative to oral steroid pulse therapy for the treatment of active vitiligo, a six month clinical trial has found.

Endocrinologists have a growing tool belt of emerging therapies at their disposal, but should they be getting a jump on detecting disease through routine CAD screening even with those who are asymptomatic?

Health minister Mark Butler says the difficult decision to scrap higher private health insurance rebates for over 65s is the right one in an

Pharmaceutical companies would be asked to own up to actual or perceived vaping and nicotine industry interests in their supply chains under a disclosure proposal from the Thoracic Society of Australia and New Zealand.